ASBP Aspire Biopharma Holdings, Inc. logo

ASBP Aspire Biopharma Holdings, Inc.

Healthcare
$5.41-3.22%ClosedMarket Cap: $624,163

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.22

P/S

18.06

EV/EBITDA

1.44

DCF Value

$-0.51

FCF Yield

-995.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

16.3%

Operating Margin

-15745.9%

Net Margin

-34039.7%

ROE

199.4%

ROA

-165.3%

ROIC

-121.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$28.4K$-3.2M$
Q4 null$4.3K$-4.7M$
FY null$6.2K$-24.5M$
Q3 null$1.9K$-1.9M$

Trading Activity

Insider Trades

View All
Fell Donald G.director
BuyTue Jun 10
Fell Donald G.director
BuyTue Jun 10
Fell Donald G.director
BuyFri Jun 06
Fell Donald G.director
BuyFri Jun 06
Wadhwani Avinash Rdirector:
SellMon Aug 28

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.21

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Peers